David Bridges
A concerning diarrhea-causing superbug has emerged in Los Angeles, raising alarms among health experts. Researchers have recently identified a troubling new strain of Shigella bacteria in the region, notable for its ability to resist nearly all available antibiotics. This development poses a significant public health threat as it highlights the growing issue of antibiotic resistance within pathogenic bacteria.
In a comprehensive study conducted by scientists at the University of California, Los Angeles, researchers examined an unusual surge of Shigella infections recorded between 2023 and 2024. Each of the cases presented an extensively drug-resistant (XDR) strain of the bacteria. While all affected individuals eventually recovered, the researchers expressed deep concern regarding the potential for this superbug to continue its spread in Los Angeles and potentially beyond, underscoring the need for increased vigilance in monitoring infectious diseases.
Shigella is a common pathogen responsible for diarrhea and various gastrointestinal issues. Typically, most infections result in a temporary illness that resolves without treatment within a week. However, severe complications can arise, particularly among individuals with compromised or underdeveloped immune systems, such as infants and young children. Alarmingly, Shigella is linked to approximately 200,000 fatalities globally each year. In the United States, it is estimated that around half a million individuals contract the infection annually, leading to thousands of hospitalizations. The bacteria primarily spread through contaminated food and water, but sexual transmission can also occur, especially among men who have sex with men, highlighting the multifaceted routes of infection transmission.
Antibiotics play a crucial role in managing severe Shigella infections or controlling outbreaks among high-risk populations. However, the bacteria have increasingly developed resistance to commonly prescribed antibiotics. The most alarming strains are classified as extensively drug-resistant, meaning they can resist multiple antibiotic classes. In their recent publication in the Journal of Infection Control, UCLA scientists provided a detailed account of a new XDR strain of Shigella sonnei identified in three patients, emphasizing the urgent need for effective treatment alternatives.
The report documented three cases detected within a brief three-month interval between 2023 and 2024. All infections were observed in men with a history of sexual activity with other men, with one individual indicating that a recent partner had been diagnosed with Shigella just a week prior. Initial laboratory analyses confirmed that these patients were infected with an XDR strain, characterized by resistance to several key antibiotics, including azithromycin, ciprofloxacin, ceftriaxone, trimethoprim-sulfamethoxazole, and ampicillin.
The scientists at UCLA performed a genetic analysis of the collected samples, revealing that all three patients harbored a similar strain of the bacteria. Notably, this strain was distinctly different from previously identified XDR strains found in other global locations, suggesting that this particular version has been evolving and circulating within the Los Angeles area for an extended period. This finding raises significant concerns about local transmission dynamics and the potential for further outbreaks.
“The identification of a novel XDR S. sonnei actively spreading in Los Angeles is alarming,” the researchers stated, emphasizing the urgency of addressing this public health threat.
Fortunately, the cases reported were still treatable, with most patients recovering without extensive medical intervention. However, one individual experienced a severe infection requiring intensive care. In this instance, the timely identification of XDR resistance prompted healthcare providers to switch to an alternative treatment regimen, which proved effective, allowing the patient to achieve full recovery. Such timely interventions are critical in managing infections caused by resistant strains.
Nevertheless, the emergence of XDR Shigella both in the U.S. and globally represents a significant and escalating public health challenge. These infections are inherently more difficult to treat than standard Shigella cases, and delays in identifying effective treatments can have dire consequences. Last year, the Centers for Disease Control and Prevention issued a public health advisory regarding the superbug. The advisory indicated that approximately 5% of Shigella infections reported to the agency in 2022 were caused by XDR strains, a significant increase from 0% in 2015. Given the recent cases, the situation is likely to have worsened further, necessitating more proactive measures to identify and control the spread of these dangerous pathogens.
“These cases underscore the rapid expansion of XDR Shigella in the U.S. and the urgent need for improved detection and management strategies,” the researchers noted, calling for immediate action to mitigate this growing threat.
Brandon Fletcher
